

REVIEW

Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women

Flavia Franconi^{1,2} and Ilaria Campesi^{2,3}

¹Department of Biomedical Sciences, University of Sassari, Sassari, Italy, ²Laboratory of Sex-Gender Medicine, National Institute of Biostructures and Biosystems, Osilo, Italy, and

³Department of Surgical, Microsurgical and Medical Sciences, University of Sassari, Sassari, Italy

Pharmacological response depends on multiple factors and one of them is sex–gender. Data on the specific effects of sex–gender on pharmacokinetics, as well as the safety and efficacy of numerous medications, are beginning to emerge. Nevertheless, the recruitment of women for clinical research is inadequate, especially during the first phases. In general, pharmacokinetic differences between males and females are more numerous and consistent than disparities in pharmacodynamics. However, sex–gender pharmacodynamic differences are now increasingly being identified at the molecular level. It is now even becoming apparent that sex–gender influences pharmacogenomics and pharmacogenetics. Sex-related differences have been reported for several parameters, and it is consistently shown that women have a worse safety profile, with drug adverse reactions being more frequent and severe in women than in men. Overall, the pharmacological status of women is less well studied than that of men and deserves much more attention. The design of clinical and preclinical studies should have a sex–gender-based approach with the aim of tailoring therapies to an individual's needs and concerns.

LINKED ARTICLES

This article is part of a themed section on Biological Sex and Cardiovascular Pharmacology. To view the other articles in this section visit <http://dx.doi.org/10.1111/bph.2014.171.issue-3>

Abbreviations

ACEI, inhibitor of angiotensin converting enzyme; ADE, adverse drug effect; ARB, antagonist of angiotensin receptor 1; CV, cardiovascular; CYP, cytochrome P450 enzymes; ET-1, endothelin-1; HMG-CoA, hydroxymethylglutaryl coenzyme A; OC, oral contraceptives; RAS, renin angiotensin system; SGD, sex–gender difference

Introduction

Optimal pharmacological therapy depends on many factors. Some of these factors are biological (metabolism, genetic and epigenetic backgrounds, age and sex) (Becquemont *et al.*, 2006), while others depend on the environment such as care provider–patient relationship. In view of the numerous biological (sex) and psychosocial-cultural (gender) differences, women and men can be considered as two different categories (Legato, 2009). However, sex–gender difference (SGD) only started to acquire the right relevance in the latter part of

the last century, although Hippocrates, describing the symptoms of gout, had written 'A woman does not take the gout unless her menses has stopped' (Enomoto and Endou, 2005), indicating a SGD in susceptibility rather than the development of a disease. The first pharmacological SGD was described in 1932 (Nicholas and Barron, 1932), when it was demonstrated that the hypnotic effect of hexobarbital lasted longer in female than in male rats. Later, it was shown that this difference is dependent on the metabolic process (Quinn *et al.*, 1958). Nowadays, SGDs in pharmacokinetic parameters are well known and have been recently and extensively

Correspondence

Professor Flavia Franconi,
Department of Biomedical
Sciences, University of Sassari,
Via Muroni 23, 07100 Sassari,
Italy. E-mail: franconi@uniss.it

Keywords

sex differences; gender
differences; drug response;
pharmacodynamics;
pharmacokinetic

Received

13 February 2013

Revised

5 August 2013

Accepted

16 August 2013

reviewed (Gandhi *et al.*, 2004; Anderson, 2005; Franconi *et al.*, 2007; 2011a,b; Soldin and Mattison, 2009). The SGDs in pharmacodynamics are not so well-known, but they are now emerging and have been recently reviewed (Legato, 2009; Maselli *et al.*, 2009; Franconi *et al.*, 2011a,b; Regitz-Zagrosek, 2012; Wang *et al.*, 2012; Marazziti *et al.*, 2013). Numerous data suggest a link between genetic polymorphisms and drug effects (Bochud and Guessous, 2012; Myburgh *et al.*, 2012), but relatively little is known about the interaction of sex-gender and pharmacogenetics on drug activity and patient outcomes. For example, hormonal substitutive therapy is associated with a significant risk to women with the platelet glycoprotein GPIIb/IIIa-TT and GP VI-TC/CC genotypes but is of benefit to women with GPIIb/IIIa-TC/CC and GP VI-TT genotypes (Bray *et al.*, 2007).

Finally, some SGDs are caused by social, educational, cultural and lifestyle factors (e.g. smoking and alcohol habits), stress, access to health care and service (Glaser *et al.*, 2000; Budeska *et al.*, 2008). In line with previous observations, poverty, low social status, domestic violence and caregiver role are related to the stress response, which lead to CV disease and diabetes mellitus (Krantz *et al.*, 1981; Muller *et al.*, 1994; Ghiadoni *et al.*, 2000; Carney *et al.*, 2001; Veronesi *et al.*, 2010; Elovainio *et al.*, 2011). Overall, these considerations strongly suggest that sex and gender are strictly and constantly associated (Marino *et al.*, 2011; Springer *et al.*, 2011). Indeed, gender is related to genetic and epigenetic variations (El-Maarri *et al.*, 2007; Zhang *et al.*, 2011a; Campesi *et al.*, 2013) that have different effects on the male and female body (Kaminsky *et al.*, 2006). It has also been found that gender can affect responses to xenobiotics (Campesi *et al.*, 2013).

Effect of diseases, access to care, influence of physician's and patient's sex on treatment and adherence

It is still not clear whether pathological conditions, such as renal, hepatic, cardiac failure and diabetes mellitus, affect pharmacodynamic and pharmacokinetic parameters in a sex-gender dependent way (Shammas and Dickstein, 1988; Hanley *et al.*, 2010; Dostalek *et al.*, 2012). However, adverse drug effects (ADEs) in heart failure occur in a sex-gender-specific manner being more prevalent in women than in men (Catananti *et al.*, 2009). Therefore, studies are needed to better understand the influence of the sex-gender element on pharmacokinetic and pharmacodynamic variations induced by pathological conditions. The therapeutic response partially depends on access to healthcare systems and psychosocial factors. The former seems to be influenced by patient sex; it has been shown that access to primary therapy for acute coronary syndrome is less easy for women than for men (Lee *et al.*, 2008; El-Menyar *et al.*, 2009; Halvorsen *et al.*, 2009). Notably, the number of drug prescriptions appears to be influenced by the sex of patients (Enriquez *et al.*, 2008) and also by the sex of the care provider; diabetic women treated by female physicians are more likely to reach their treatment goals than if treated by men (Journath *et al.*, 2010). Interestingly, being a woman is a negative predictor for therapy

adherence after acute coronary syndrome and myocardial infarction (Butler *et al.*, 2002; Jackevicius *et al.*, 2008; Lee *et al.*, 2008; Peterson *et al.*, 2008; Tuppin *et al.*, 2009; Mosca *et al.*, 2011; Kirchmayer *et al.*, 2012; Kumbhani *et al.*, 2013), and in hypertension (Mazzaglia *et al.*, 2009). This finding could partly be as a result of there being more women in the elderly population than men (Mazzaglia *et al.*, 2009). However, these findings do suggest that there is a need for physicians to adopt specifically tailored programmes to improve evidence-based care in women with acute myocardial infarction. A better awareness of all the components that influence treatment and adherence could improve clinical outcomes in women with CV disease.

Is the actual clinical trial design able to incorporate SGDs?

Nowadays, it is clear that sex-gender potentially affects a multitude of parameters from conception to death (Institute of Medicine, 2010), and so this dimension should be considered in the design, enrolment, analysis and reporting of data to avoid slowing down progress in improving health and medicine. It is evident that consideration of SGDs is critical in the development of medications, and therefore both men and women should be enrolled in clinical investigations. Nowadays, with the exception of CV diseases and sex-unrelated cancers, women are routinely recruited, at least in phase 3 clinical trials (Raz and Miller, 2012). However, there are still fewer females than males participating in phase 1 and phase 2 trials (Pinnow *et al.*, 2009), despite the regulatory agencies of USA and Canada stipulating that women should be included in clinical trials (Health Canada, 1997; FDA, 2010).

Phase 1 clinical trials of a drug start when sufficient animal data have been accumulated establishing that the compound has a reasonably safe profile and is likely to have a therapeutic effect. Therefore, it is necessary to have experimental animal models that are predictive for SGDs in humans, but suitable models are not always available (Mugford and Kedderis, 1998; Franconi *et al.*, 2008; Mahmoodzadeh *et al.*, 2012). The limited recruitment of women, under-utilization of female animals and the use of non-predictive models in preclinical studies all contribute to a lack of knowledge and awareness of SGDs in drug response. Also, difficulties in the translation of data obtained in males to females ultimately leads to less appropriate therapy for women (Johnell *et al.*, 2009). So, both preclinical and clinical studies require a sex-gender approach in the development of drugs in order to improve translational medicine (Raz and Miller, 2012). Hence, the cyclic hormonal fluctuations of females and the events of reproductive life (pregnancy and lactation), which now contribute to the exclusion of women from clinical trials and of female animals from preclinical studies (Miller *et al.*, 2011; Spoletini *et al.*, 2012), should be incorporated in the experimental paradigms. Indeed, pregnancy produces important changes in the female body that might modify pharmacokinetic parameters of medications (Anger and Piquette-Miller, 2008), and considering that 96% of pregnant women consume at least one drug (Weiner *et al.*, 2005), this is an imperative problem.

Endogenous and exogenous sexual hormones can affect pharmacodynamics and pharmacokinetics directly and indirectly, as sex hormones affect drug responses and some drugs modify hormonal signalling pathways (Franconi *et al.*, 2007; Spoletini *et al.*, 2012). Numerous reviews have focused on strategies and methods that optimize sex–gender research in different fields (Gillies and McArthur, 2010; Miller *et al.*, 2011). However, to optimize the design of clinical studies, identification of the role sex–gender has in the placebo response is urgently required (Saxon *et al.*, 2001; Franconi *et al.*, 2007; 2012; Greenspan *et al.*, 2007; Aslaksen and Flaten, 2008; Haltia *et al.*, 2008; Aslaksen *et al.*, 2011), either for the investigators or for the patients, because the placebo effect may be an integral part of the therapy (Ross and Buckalew, 1985). Although at this stage it has not been possible to reach any firm conclusions, in view of the importance of social factors and the biological differences involved in the placebo effect, SGDs are plausible.

Pharmacokinetic differences including bioequivalence studies

The SGDs in pharmacokinetics have been recently reviewed (Gandhi *et al.*, 2004; Anderson, 2005; Schwartz, 2007; Franconi *et al.*, 2011a,b; Wang *et al.*, 2012), and they include all pharmacokinetic parameters. A great number of SGDs have been demonstrated in the gastrointestinal system; for example gastric pH is higher in women than men, whereas gastric and bowel transit times are lower (Freire *et al.*, 2011). Some of these differences are progesterone- and oestrogen-dependent, being influenced by the phase of the menstrual cycle or pregnancy. Luminal pH and gastrointestinal motility can have a significant effect on drug bioavailability, influencing the rate of drug dissolution and the transit time, which could lead, for example, to an increased waiting time for taking the drug after meals. Some SDGs in metabolic enzymes are reported in Table 1, many of which concern isoforms of the cytochrome P450 system belonging to 1, 2 and 3 CYP families, which catalyze the oxidative biotransformation of many drugs. Indeed, sex-specific expression of CYP isoforms is common in rodents (Waxman and Holloway, 2009), but is more subtle in humans (Gandhi *et al.*, 2004; Schwartz, 2007; Waxman and Holloway, 2009; Zhang *et al.*, 2011b). The most important CYP isoform in drug metabolism is CYP3A4, which has a higher level of expression in female livers than in males (Parkinson *et al.*, 2004; Waxman and Holloway, 2009). Table 1 also shows SGDs in transporters and multiple drug resistance proteins. Genetic polymorphisms of drug transporters have been demonstrated extensively (Buist *et al.*, 2002; Morris *et al.*, 2003; Groves *et al.*, 2006; Burckhardt, 2012; Emami Riedmaier *et al.*, 2012). Expression of P-glycoprotein, also known as multidrug resistance protein, differs between men and women; for example hepatic expression is 2.4-fold lower in females, although there are large inter-individual differences in P-glycoprotein levels (Schuetz *et al.*, 1995). However, little is known about SGDs in P-glycoprotein function at the blood–brain barrier, which again may be influenced by sex–gender-specific hormones (Bebawy and Chetty, 2009). Although it has been shown that

age induces a decline in the P-glycoprotein function of the blood–brain barrier in men but not in women (van Assema *et al.*, 2012).

Considering that a great number of drugs can be found in generic form, we recollect that bioequivalence studies of the generic versus reference drug are carried out mostly in adult young men (European Medicines Agency, 2010), disregarding the fact that these drugs are also used by women. However, the inactive ingredients may affect the bioavailability of generics and this could occur in a sex-specific way, at least in some cases. For example, polyethylene glycol enhances the bioavailability of ranitidine in men (up to 63%), whereas it is decreased in women (up to 24%) (Ashiru *et al.*, 2008). Furthermore, women may develop more ADEs than men arising from different inactive ingredients (Kando *et al.*, 1995; Soldin *et al.*, 2011), which may affect the safety profile of a medication. In conclusion, SGD should also be included as a variable in bioequivalence studies (Wolbrette, 2002), especially for drugs that prolong QT interval and have a narrow therapeutic index.

Pharmacodynamics and pharmacogenomics

The SGDs in pharmacodynamics are more difficult to demonstrate because more male than female animals are used in experimental studies, while cells are often considered to be without sex (Maselli *et al.*, 2009; Miller *et al.*, 2011). However, in the last few years, the number of studies demonstrating SGDs at the molecular level has increased, and numerous pharmacological targets have been investigated (Antoniucci *et al.*, 2001; Drici and Clement, 2001; Cross *et al.*, 2002; Leinwand, 2003; Mendelsohn and Karas, 2005; Pretorius *et al.*, 2005; Franconi *et al.*, 2007; 2011a,b; Regitz-Zagrosek and Seeland, 2012). It has also been shown that many genetic polymorphisms present sex–gender specificity (Myburgh *et al.*, 2012). It is not possible to examine all drugs, and thus we have focused our attention on some CV agents, as CV disease represents the major cause of mortality in women and in men (Nichols *et al.*, 2012), and SGDs in the prevention, diagnosis and outcomes of this disease have been demonstrated (Stramba-Badiale *et al.*, 2006).

Inhibitors of angiotensin converting enzyme (ACEIs), antagonists of angiotensin receptors 1 (ARBs), renin inhibitors and aldosterone antagonists

Sex–gender has an important influence on BP; premenopausal women have, for example, a lower arterial BP than age-matched men (Dubey *et al.*, 2002). However, a positive correlation between BP and coronary risk appears to be true for both men and women, regardless of age (Turnbull *et al.*, 2010). The prevalence and also the control of hypertension differ between the sexes. The assessment and management of cardiovascular (CV) risk can vary with patient sex, women being disproportionately affected (Turnbull *et al.*, 2011). It is not yet clear whether BP-lowering treatments provide similar protection against major CV events in men and women.

Table 1

Some sex–gender differences in the expression and/or activity of enzymes and transporters involved in drug metabolism or drug activity

Enzymes	Predominant sex	Substrates	Observations	References
Acetylcholinesterase	+ M (human) = rat	Acetylcholine		(Alves-Amaral <i>et al.</i> , 2010; Zimmer <i>et al.</i> , 2012)
Butyrylcholinesterase	+ F (rat) + M (human)	Succinylcholine, ester-type local anesthetics, cocaine		(Alves-Amaral <i>et al.</i> , 2010; Zimmer <i>et al.</i> , 2012)
Alcohol dehydrogenase 1	+ F	Cyclophosphamide		(Huang <i>et al.</i> , 2011)
Carboxylesterase 1	= (murine)	Methylphenidate, oseltamivir, irinotecan	Inducer: Phenobarbital	(Zhu <i>et al.</i> , 2009)
Carboxylesterase 2	= murine	Prasugrel, fans		(Zhu <i>et al.</i> , 2009)
Carboxylesterase 3	+ M (rat)	Irinotecan, capecitabine		(Huang <i>et al.</i> , 2011)
Carboxylesterase 4	+ M (rat)			(Huang <i>et al.</i> , 2011)
Catechol-O-methyl transferase	+ M	Dopamine, noradrenaline, adrenaline, levodopa, azathioprine		(Franconi <i>et al.</i> , 2007; Soldin and Mattison, 2009)
CYP1A2	+ M	Caffeine, clozapine, steroids, flutamide, lidocaine, mexiletine	Inducer: coffee, smoking, charcoal-grilled meat, omeprazole, carbamazepine, rifampicin Inhibitor: fluvoxamine cimetidine, ciprofloxacin, disulfiram, OC	(Anderson and Walton, 2005; Zanger and Schwab, 2013)
CYP2A6	+ F	Nicotine	In fertile age, is increased by OC	(Benowitz <i>et al.</i> , 2006)
CYP2B6	+ M	Cyclophosphamide, thiotepa, procarbazine,	Inducer: St. John's wort, rifampicin, phenytoin, phenobarbital	(Zanger and Schwab, 2013)
CYP2C9	=	Losartan, irbesartan, candesartan, valsartan		(Hallberg <i>et al.</i> , 2002; Anderson and Walton, 2005; Zanger and Schwab, 2013)
CYP2C19	=		OC influence it	(Anderson and Walton, 2005; Zanger and Schwab, 2013)
CYP2D6	+ M	Dacarbazine, cisplatin etoposide, etoposide, propranolol, metoprolol, tamoxifen, ondansetron, nortryptiline	Inhibitor: fluoxetine, paroxetine, quinidine	(Schwartz, 2007; Zanger and Schwab, 2013)
CYP2E1	+ M	Dacarbazine, cisplatin, etoposide		(Huang <i>et al.</i> , 2011)
CYP3A4 (liver)	+ F	Verapamil, midazolam, triazolam, alprazolam, nifedipine, zolpidem, imatinib, sunitinib, budesonide	Inhibitor: erythromycin, ethinylestradiol, ketoconazole Inducer: rifampicin, Ginkgo biloba, glucosteroids, statins, barbiturates, St. John's wort	(Huang <i>et al.</i> , 2011; Zanger and Schwab, 2013)
Dihydropyrimidine dehydrogenase	+ M	6-Mercaptopurine, fluorouracil		(Yamashita <i>et al.</i> , 2002; Franconi <i>et al.</i> , 2007)
Glutathione S- Transferase	+ M (rat)		Inducer: phenobarbital	(Higgins and Hayes, 2011; Huang <i>et al.</i> , 2011)

Table 1

Continued

Enzymes	Predominant sex	Substrates	Observations	References
Hydroxysteroid sulfotransferase	+ F (murine)		Inducer: caffeine only in intestine and liver of female rats	(Wu <i>et al.</i> , 2001; Maiti and Chen, 2003; Zhou <i>et al.</i> , 2012)
Aryl sulfotransferases	+ M (rat)	Oestrogen, thyroid hormones	Inducer: tamoxifen	(Maiti and Chen, 2003; Zhou <i>et al.</i> , 2012)
Thiopurine methyl transferase	+ M	6-Mercaptopurine		(Franconi <i>et al.</i> , 2007)
UDP-glucuronosyl-transferases	+ M (Ugt2b1 (liver) Ugt2b5/37/38 (kidney), and Ugt1a6 (lung) UGT2B17 + F Ugt1a1, Ugt1a5 (liver) Ugt1a2 (kidney) brain Ugt2b35	Steroid hormones, acetaminophen	Influenced by diet Inducer: smoking and alcohol	(Buckley and Klaassen, 2007; Gallagher <i>et al.</i> , 2010; Navarro <i>et al.</i> , 2011)
Renal Transporters				
Organic Anion Transporter 1	+ M rat = in rabbit	ACEI, ARB, thiazides, furosemide, penicillins, cephalosporins, quino-lones, tetracyclines, aminoglycosides, macrolides, cimetidine, ranitidine, fluvastatin, pravastatin, simvastatin	Inhibitor: rifampicin	(Buist <i>et al.</i> , 2002; Emami Riedmaier <i>et al.</i> , 2012)
Organic Anion Transporter 2	+ F rat = rabbit	Loop and thiazide diuretics, cephalosporins, tetracyclines, erythromycin, 5-fluorouracil		(Groves <i>et al.</i> , 2006; Emami Riedmaier <i>et al.</i> , 2012)
Organic Anion Transporter 3	= rat, rabbit	Bumetanide, ethacrynate, furosemide, penicillin, diclofenac, ibuprofen, indomethacin, ketoprofen		(Emami Riedmaier <i>et al.</i> , 2012)
Organic Anion Transporter 5	+ F (rat)	Furosemide, benzylpenicillin, diclofenac, ibuprofen, salicylate		(Emami Riedmaier <i>et al.</i> , 2012)
Urate Transporter 1	+ M (rat, human)	Salicylate, phenylbutazone, sulfinpyrazone, indomethacin, losartan, prazosartan, telmisartan, furosemide, benzylpenicillin		(Emami Riedmaier <i>et al.</i> , 2012)
Liver and intestinal transporters				
Oatp1	= rat			(Rost <i>et al.</i> , 2005)
Oatp2	= rat			(Rost <i>et al.</i> , 2005)
Oatp4	+ F = (rat)			(Li <i>et al.</i> , 2002; Rost <i>et al.</i> , 2005)
Multidrug resistance protein				
Mrp2	+ F		High-fat diet reduces hepatic Mrp2 expression only in female	(Rost <i>et al.</i> , 2005; Lu and Klaassen, 2008; Kong <i>et al.</i> , 2012)
Mrp3	+ F			(Rost <i>et al.</i> , 2005)

F = female, M = male.

Differences in CV risks between sexes are unlikely to reflect differences in response to BP-lowering treatments (Turnbull *et al.*, 2008).

ACEIs and ARBs are integral components of CV therapy. The renin angiotensin system (RAS) shows sexual dimorphism; sex hormones affect the RAS at multiple levels. In particular, oestrogens increase the availability of angiotensinogen and plasma levels of angiotensin II, but decrease renin and ACE activities, and the expression of angiotensin receptor 1, while androgens up-regulate the RAS system (Fischer *et al.*, 2002). A lower percentage of women have been included in clinical trials with ACEIs and ARBs in comparison with men, and many of these were not designed to incorporate SGDs (Stramba-Badiale, 2009; Seeland and Regitz-Zagrosek, 2012). One meta-analysis showed that ACEIs are less effective in reducing mortality in women with symptomatic heart failure than in men, whereas these agents do not modify the survival rate in women with asymptomatic heart failure (Shekelle *et al.*, 2003). In women at high CV risk, ACEIs reduce CV events when used for secondary prevention (Seeland and Regitz-Zagrosek, 2012). However, results from an Australian study demonstrated that ACEIs decrease CV events in men but not in women (Wing *et al.*, 2003). More recently, it has also been shown that some sex disparities depend on genetic differences. A genetic variant of the ACE-1 enzyme (I and D alleles) affects the therapeutic response to ACEIs; ACEIs are more renoprotective in women with the D/D genotype compared to D/D men, while in D/D men, they are more effective in those with the I/D than the I/I genotype (Ruggenti *et al.*, 2008). The ACE gene I/D polymorphism, which is linked to increased plasma levels of ACE and with a major risk for CV disease (Kumar *et al.*, 2009), also affects the hypotensive effect of hydrochlorothiazide in a sex-gender specific manner. The genotypes associated with the greatest responses to hydrochlorothiazide are II homozygotes and D/D in women and men, respectively (Schwartz *et al.*, 2002).

During treatment with ACEI, cough and angioedema are more frequent in women than in men (Slater *et al.*, 1988; Mackay *et al.*, 1999). Recently, it has been observed that the XPNPEP2 C-2399A genotype, which in individuals produces higher plasma levels of aminopeptidase-inactivated metabolites, is associated with an increased frequency of ACEI-associated angioedema in all men, especially black men, but not in white men and women (Woodard-Grice *et al.*, 2010). However, ACEI-related cough seems to be associated with polymorphism of the bradykinin B₂ receptor (for correct receptor nomenclature see Alexander *et al.*, 2013), the effect of this polymorphism being sex-specific (Mas *et al.*, 2011). Finally, the majority of women discontinue ACEI therapy due to cough, while the majority of men stop treatment because of hypotension (Shah *et al.*, 2000).

Another class of compounds that affects the RAS is defined by renin inhibition. The first direct inhibitor of renin, aliskiren, shows the same efficacy as an anti-hypertensive in men and women. Even though the area under the plasma concentration-time curve and maximal concentration of aliskiren were lower in men than in women, adjustment of individual values for overall mean body weight abolished these gender differences (Jarugula *et al.*, 2010; Seeland and Regitz-Zagrosek, 2012).

Aldosterone, the primary mineralocorticoid secreted by the adrenal gland, is also implicated in the pathogenesis of CV disease (Rocha and Stier, 2001). Results of the Framingham Heart Study indicated that serum levels of aldosterone are directly related to cardiac wall thickness in women, but not in men (Vasan *et al.*, 2004), suggesting that women are more at risk from the harmful effects of aldosterone than men (Duprez, 2004). In two clinical trials, RALES (Randomized Aldactone Evaluation Study) and EPHEUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Study), it was shown that spironolactone and eplerenone, selective aldosterone antagonists, were effective at reducing mortality in heart failure patients (Pitt *et al.*, 1999; 2003). However, it is not yet known whether these agents have sex-specific effects in relation to treatment of post-myocardial infarction. At 30 days, when all causes of mortality were considered, the eplerenone study showed a trend towards a greater benefit for women in comparison with men. However, at 16 months, when CV death or hospitalization for CV events was considered, there was a trend for a greater benefit in men than in women. The RALES trial, which examined the effect of spironolactone in symptomatic heart failure patients, showed no sex differences. However, it is important to note that only about 30% of the patients participating in these trials were women, therefore, no firm conclusions can be drawn from the results. In animal models, the aldosterone antagonists reduced the infarct size in male, but not female mice and rats (Rigsby *et al.*, 2007; Frieler *et al.*, 2012). Additionally, spironolactone was shown to lower BP only in male rats on a high-salt diet (Michaelis *et al.*, 2012), whereas eplerenone is more effective in reducing myocardial infarction-induced cardiac remodelling in female rats, and also, at restoring altered gene expression (Kanashiro-Takeuchi *et al.*, 2009).

Calcium channel blockers

Calcium channel blocking agents are mainly prescribed for CV disease, particularly for hypertension and as a prophylaxis against angina. Some of these agents, such as verapamil and amlodipine, show sexual dimorphism in their pharmacokinetics. In particular, men have a faster clearance of sustained release or p.o. administered verapamil than women (Krecic-Shepard *et al.*, 2000), but not after i.v. injection. Interestingly, the mean plasma level of each verapamil enantiomer is higher in women than in men at all time points after administration of a controlled release preparation (Gupta *et al.*, 1995). Hence, the different effects seen after p.o. and i.v. administration could be attributed to the higher activity of CYP3A4 or lower activity of P-glycoprotein in women compared with men, or both factors (Dadashzadeh *et al.*, 2006). Indeed, it has been shown that the bioavailability of amlodipine is slightly higher in women than in men, but these differences were attributed to the lower body weight of women, because when data were adjusted for weight, the bioavailability did not differ (Abad-Santos *et al.*, 2005). There are a few sex-gender pharmacodynamic differences: women treated with verapamil, especially the elderly, experienced a greater BP reduction than men (Jochmann *et al.*, 2005). Indeed, Krecic-Shepard *et al.* (2000) showed that in hypertensive women, verapamil produces a greater heart rate than in men. The long-acting calcium antagonist amlodipine, after

adjustment of dose for body weight, leads to a larger BP reduction in women than in men, and this depends on the use of hormonal replacement therapy (Kloner *et al.*, 1996). The same study showed that women have a higher incidence of oedema than men. Finally, in the HOT (Hypertension Optimal Treatment) study with felodipine, which was administered alone or, if necessary, in combination with other anti-hypertensives, the target diastolic BP was not reached, with or without the addition of aspirin. It was also demonstrated that the incidence of acute myocardial infarction is significantly less in women with a lower diastolic BP target (<80 and <85 mmHg) compared with those with a higher BP target value (<90 mmHg). This trend was not significant in men, although the effect of aspirin was more marked (Kjeldsen *et al.*, 2000). Finally, a recent study showed that the combination olmesartan and amlodipine induces a small but significant reduction in diastolic and systolic BP, the reduction being higher in women than in men (Schmieder and Bohm, 2011). With another dihydropyridine calcium antagonist, nifedipine, more drug-related adverse events were observed in women (15.8%) than in men (9.8%) (Fan *et al.*, 2008). In contrast, pharmacokinetic parameters determined after a single dose of diltiazem did not differ between men and women (Yeung *et al.*, 1993; Saenz-Campos *et al.*, 1995), although some differences in haemodynamic responses have been detected (Klassen *et al.*, 1995). However, these studies were very small, and so it is difficult to reach any definitive conclusion.

β -Adrenoceptor antagonists

The activity of the CV system is also strictly controlled by the noradrenergic system, which presents numerous SGDs. Generally, sympathetic nerve activity is more elevated in men than in women of the same age (Hart and Joyner, 2010). In young men, but not in young women, muscle sympathetic nerve activity is positively related to total peripheral resistance (Hart and Joyner, 2010). Women have an elevated cardiac noradrenaline spillover, indicating that they have a greater cardiac-specific sympathetic activation than men (Mitoff *et al.*, 2011). Women are less responsive to sympathetic vasoconstrictor activity than men (Momen *et al.*, 2010). Importantly, β_2 -adrenoceptor sensitivity is increased in young women compared with men (Kneale *et al.*, 2000), and young women have a higher density of β_2 -adrenoceptors in lymphocytes (Wheeldon *et al.*, 1994; Mills *et al.*, 1996). These differences in β_2 -adrenoceptor signalling could explain the greater vasoconstrictor sensitivity to noradrenaline in men.

β -Adrenoceptor antagonists are among the most widely prescribed drugs. In particular, they show numerous sex-gender pharmacokinetic differences, which predominate in those agents metabolized by CYP2D6, such as metoprolol and propranolol (Luzier *et al.*, 1999). Notably, oral contraceptives (OC) increase the plasma concentration of metoprolol (Franconi *et al.*, 2011a). β -Adrenoceptor antagonists elevate aortic wave reflection both in young men and women, but they are more effective in women (Lieber *et al.*, 2010; Casey *et al.*, 2011; 2012); it is notable that the effects of these antagonists are mediated by sex specific mechanisms (Casey *et al.*, 2012). However, these clinical studies with β -adrenoceptor antagonists have involved only a small

number of women and often their number is not sufficient to reach significance. This could also explain the equivocal results obtained on the efficacy of β -adrenoceptor antagonists in treatment of heart failure (Seeland and Regitz-Zagrosek, 2012).

Endothelin-1 antagonists

The potent vasoconstrictor endothelin-1 (ET-1) presents some sex-gender specificity, as recently reviewed (Seeland and Regitz-Zagrosek, 2012). In particular, in animal models, males express more ET-1 and have a greater endothelin receptor A-mediated response (Kittikulsuth *et al.*, 2013). Men have higher concentrations of circulating ET-1 and a more pronounced ET-mediated coronary vasoconstriction than women. In addition, genetic polymorphisms of the ET system are more likely to be associated with hypertension and renal injury in women than in men (Kittikulsuth *et al.*, 2013). Some SGDs have also been seen during the treatment of pulmonary hypertension with endothelin antagonists, indicating the superior therapeutic benefit of these drugs in women compared to men (Gabler *et al.*, 2012).

Statins

Statins are global leaders as therapeutics for dyslipidemia, being largely used for the primary and secondary prevention of CV disease. They inhibit the rate-limiting enzyme hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase. Notably, in experimental models, oestrogens prevent the conversion of HMG-CoA to mevalonate (Ness and Chambers, 2000). However, the use of statins for primary prevention of CV disease among women is still a matter of debate (Mosca, 2012), because only a few women have ever participated in primary prevention trials, and women have a lower short-term absolute risk of CV events, strengthening the challenge of women being under-represented in clinical trials. Indeed, a recent meta-analysis suggests that statins could have some benefit in the primary prevention of CV disease in women (Kostis *et al.*, 2012). For primary prevention, it was found that the average number of patients who need to be treated to observe one bad outcome over 4 years was 148 women compared to 43 men, while for secondary prevention, these numbers are 36 for women and 29 for men (Kostis, 2012). However, the Kostis' meta-analysis covered a relatively short study period, which means there are still some concerns over the long-term safety of statins. In fact, a longer term study of statin use for primary prevention showed a potential risk of diabetes mellitus (Sattar *et al.*, 2010) depending on the dose and on the individual statin administered (Navarese *et al.*, 2013). Whereas in another meta-analysis, the benefits of statin treatment and risk of diabetes were less clear in women than in men, especially if the statins were used for primary prevention and in young women (Ma *et al.*, 2012). Muscular side effects, such as myalgia, with or without an elevation in serum CK, cramps and weakness, have frequently been associated with the use of statins, with myopathy being more frequent in women than in men (Bellosa *et al.*, 2004; Baigent *et al.*, 2010). These side effects have led to approximately 30% of the symptomatic patients ceasing to take the statins, with the dropout rate being higher in women than in men (Rosenbaum *et al.*, 2012).

Aspirin and antiplatelet therapy

Numerous SGD's have been described for the biology of platelets (Johnson *et al.*, 1975; Faraday *et al.*, 1997; Kurrelmeyer *et al.*, 2003; Yee *et al.*, 2005; Eidelman *et al.*, 2010). In particular, it has been observed that after puberty, women have consistently more platelets than men, and the age-induced decrease in platelet count is more in men than in women (Biino *et al.*, 2013). Both megakaryocytes and circulating platelets express receptors for sex steroids (Miller *et al.*, 2008), but their role in platelet biology has not been clarified. Indeed, the menstrual cycle does not affect platelet aggregation (Kurrelmeyer *et al.*, 2003; Eidelman *et al.*, 2010), while OC promote it (Braunstein *et al.*, 2002). Experimental data in mice have shown that oestrogens through oestrogen receptor (ER)- α decrease platelet aggregability *ex vivo* and *in vivo* (Valera *et al.*, 2012). In addition, oestrogens modulate the expression of platelet proteins, including β 1 tubulin, which may affect platelet production and activation (Valera *et al.*, 2012). Tamoxifen inhibits platelet aggregation (Nayak *et al.*, 2011), suggesting that oestrogens could play a role in platelet biology. However, the findings of Valera *et al.* (2012) and Nayak *et al.* (2011) seem to be contradictory; it is known that tamoxifen behaves as a mixed agonist/antagonist of oestrogen receptors depending on the sensitivity of the tissue to oestrogen (Powles *et al.*, 1996; Cohen *et al.*, 2008).

Genetic polymorphisms for platelet glycoproteins are associated with risk of atherothrombotic events (Weiss *et al.*, 1996; Bray, 2000; Zotz *et al.*, 2000), but it is not known if they are influenced by sex-gender. However, women heterozygotes and homozygotes for the GPIIb- α -5C allele, have a higher incidence of a composite end point (death, myocardial infarct or unstable angina) compared with those homozygous for the GPIIb- α -5T allele (Bray *et al.*, 2007). Hormone replacement therapy is associated with a 46% lower adjusted CV risk in women with the -5C allele versus the -5TT genotype (Bray *et al.*, 2007).

The SGD's in aspirin and antiplatelet therapy have recently been reviewed (Franconi *et al.*, 2011b; Wang *et al.*, 2012) and it has emerged that there is a gap in the systematic knowledge regarding platelet biology, genomics and response to antiplatelet therapy, which is partly due to an underrepresentation of women in clinical trials (Melloni *et al.*, 2010). This deficiency should be overcome by increasing our knowledge of platelet biology, including the role of platelet oestrogen and androgen receptors and the influence of pharmacogenomics.

Adverse drug effects (ADEs)

Women have a higher rate and a major severity of ADEs (Pirmohamed *et al.*, 2004; Patel *et al.*, 2007; Franconi *et al.*, 2011b). Indeed, risk factors for ADE, such as polytherapy, aging and depression, are more frequent in women than in men (Pirmohamed *et al.*, 2004; Patel *et al.*, 2007; Zender and Olshansky, 2009; Sikdar *et al.*, 2010; Franconi *et al.*, 2011b). Female sex-gender appears to be a potential risk factor for ADEs, such as iatrogenic long QT syndrome, thiazolidinedione-induced bone fracture and iatrogenic systemic lupus erythematosus (Borchers *et al.*, 2007; Jones *et al.*,

2009; Rivero and Curtis, 2010; Franconi *et al.*, 2011b). Numerous medications can prolong the QT interval, such as antiarrhythmics, anti-infective drugs, antipsychotics, gastrointestinal stimulants, antihistaminics and opioid analgesics. Notably, the SGD's in QT duration are age- and hormone-dependent (Kurokawa and Furukawa, 2013). Susceptibility to drug-induced arrhythmias is higher when the oestrogen level is higher (James *et al.*, 2007) and lower when the progesterone level is high (Janse de Jonge *et al.*, 2001; Nakagawa *et al.*, 2006). Some SGD's may arise directly from cardiac tissue; for example female hearts express fewer of the K ion channel subunits hERG, minK, $K_{IR}2.3$, $K_v1.4$, K_v channel-interacting protein 2 (KChIP2), SUR2 and $K_{IR}6.2$, and also connexin43 and phospholamban compared with male hearts (Di Diego *et al.*, 2002; Fish and Antzelevitch, 2003; Gaborit *et al.*, 2010; Nattel *et al.*, 2010). Additionally, hypokalaemia, hyponatraemia induced by antihypertensive agents, nausea, vomiting and haematological toxicity induced by antineoplastics, bleeding induced by anticoagulants and salicylates, antipsychotic drug-induced weight gain, and metabolic syndrome are more frequent and severe in women than in men (van Kuilenburg *et al.*, 2004; Haack *et al.*, 2009; Regitz-Zagrosek and Seeland, 2012). In conclusion, ADEs represent a source of greater health concern in women than in men and, therefore, need to be investigated further and in more depth.

Perspectives

The epidemiology, natural history, prophylaxis and therapy of diseases are strongly influenced by sex-gender, and therefore, it is time to include sex-gender at each stage of drug development. In women, sex steroid hormone fluctuations should be included in the design of studies, but it should also be mandatory to determine whether females are using exogenous hormones (including phytoestrogens) and drugs that interfere with hormonal signalling in view of the bidirectional relationship between sex hormones and drugs. Of course, men should be included in clinical trials for the diseases where the disadvantage predominates in the male sex, as in the case of breast cancer and hemiparesis.

In the future, it is of major importance to carry out definitive studies in order to gain a more detailed knowledge of SGD's. The design of clinical and preclinical studies should have a gender-based approach with a view to reaching proper conclusions for both sexes and to reduce the time for translation of research results into daily clinical practice. Furthermore, it is vitally important to reduce ADEs because of their high individual, social and economic effects. Psychological factors and the environment appear to be involved in the pathogenesis and progression of CV diseases, so the influence of specific elements should be evaluated with the aim of tailoring therapies to an individual's needs and concerns. At a fundamental level, it is a matter of paramount importance to increase drug efficacy, safety profile, adherence and compliance to therapy.

Acknowledgements

Supported by a grant of Legge Regionale n. 7: 'Promozione della ricerca scientifica e dell'innovazione tecnologica in

Sardegna' and by a grant of Regione Sardegna 'Progetti difarmacovigilanza attiva, finanziabili attraverso i fondi fv 2008/09'. We are grateful to the Major of Osilo and all Municipal Hall for the laboratory space that they dedicate to the National Sex –Gender Laboratory.

Conflict of interest

None.

References

- Abad-Santos F, Novalbos J, Galvez-Mugica MA, Gallego-Sandin S, Almeida S, Vallee F *et al.* (2005). Assessment of sex differences in pharmacokinetics and pharmacodynamics of amlodipine in a bioequivalence study. *Pharmacol Res* 51: 445–452.
- Alexander SPH *et al.* (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. *Br J Pharmacol* 170: 1449–1867.
- Alves-Amaral G, Pires-Oliveira M, Andrade-Lopes AL, Chiavegatti T, Godinho RO (2010). Gender-related differences in circadian rhythm of rat plasma acetyl- and butyrylcholinesterase: effects of sex hormone withdrawal. *Chem Biol Interact* 186: 9–15.
- Anderson GD (2005). Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. *Clin Pharmacokinet* 44: 989–1008.
- Anderson R, Walton M (2005). Contraceptive choices: is the future with men? *Womens Health (Lond Engl)* 1: 183–189.
- Anger GJ, Piquette-Miller M (2008). Pharmacokinetic studies in pregnant women. *Clin Pharmacol Ther* 83: 184–187.
- Antoniucci D, Miller VM, Sieck GC, Fitzpatrick LA (2001). Gender-related differences in proliferative responses of vascular smooth muscle cells to endothelin-1. *Endothelium* 8: 137–145.
- Ashiru DA, Patel R, Basit AW (2008). Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. *Pharm Res* 25: 2327–2333.
- Aslaksen PM, Flaten MA (2008). The roles of physiological and subjective stress in the effectiveness of a placebo on experimentally induced pain. *Psychosom Med* 70: 811–818.
- Aslaksen PM, Bystad M, Vambheim SM, Flaten MA (2011). Gender differences in placebo analgesia: event-related potentials and emotional modulation. *Psychosom Med* 73: 193–199.
- van Assema DM, Lubberink M, Rizzu P, van Swieten JC, Schuit RC, Eriksson J *et al.* (2012). Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. *EJNMMI Res* 2: 57–62.
- Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N *et al.* (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 376: 1670–1681.
- Bebawy M, Chetty M (2009). Gender differences in p-glycoprotein expression and function: effects on drug disposition and outcome. *Curr Drug Metab* 10: 322–328.
- Bequemont L, Verstuyft C, Jaillon P (2006). [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants]. *Bull Acad Natl Med* 190: 37–49; discussion 50–33.
- Bellosta S, Paoletti R, Corsini A (2004). Safety of statins: focus on clinical pharmacokinetics and drug interactions. *Circulation* 109: III50–III57.
- Benowitz NL, Lessor-Schlaggar CN, Swan GE, Jacob P, 3rd (2006). Female sex and oral contraceptive use accelerate nicotine metabolism. *Clin Pharmacol Ther* 79: 480–488.
- Biino G, Santimone I, Minelli C, Sorice R, Frongia B, Traglia M *et al.* (2013). Age- and sex-related variations in platelet count in Italy: a proposal of reference ranges based on 40987 subjects' data. *PLoS ONE* 8: e54289.
- Bochud M, Guessous I (2012). Gene-environment interactions of selected pharmacogenes in arterial hypertension. *Expert Rev Clin Pharmacol* 5: 677–686.
- Borchers AT, Keen CL, Gershwin ME (2007). Drug-induced lupus. *Ann N Y Acad Sci* 1108: 166–182.
- Braunstein JB, Kershner DW, Bray P, Gerstenblith G, Schulman SP, Post WS *et al.* (2002). Interaction of hemostatic genetics with hormone therapy: new insights to explain arterial thrombosis in postmenopausal women. *Chest* 121: 906–920.
- Bray PF (2000). Platelet glycoprotein polymorphisms as risk factors for thrombosis. *Curr Opin Hematol* 7: 284–289.
- Bray PF, Howard TD, Vittinghoff E, Sane DC, Herrington DM (2007). Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. *Blood* 109: 1862–1869.
- Buckley DB, Klaassen CD (2007). Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. *Drug Metab Dispos* 35: 121–127.
- Budeska T, Egnor E, Howell L (2008). Gender Influence on Perceptions of Healthy and Unhealthy Lifestyles. Vol. All Volumes (2001–2008). Paper 3.
- Buist SC, Cherrington NJ, Choudhuri S, Hartley DP, Klaassen CD (2002). Gender-specific and developmental influences on the expression of rat organic anion transporters. *J Pharmacol Exp Ther* 301: 145–151.
- Burckhardt G (2012). Drug transport by Organic Anion Transporters (OATs). *Pharmacol Ther* 136: 106–130.
- Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA *et al.* (2002). Outpatient adherence to beta-blocker therapy after acute myocardial infarction. *J Am Coll Cardiol* 40: 1589–1595.
- Campesi I, Carru C, Zinellu A, Occhioni S, Sanna M, Palermo M *et al.* (2013). Regular cigarette smoking influences the transsulfuration pathway, endothelial function, and inflammation biomarkers in a sex-gender specific manner in healthy young humans. *Am J Transl Res* 5: 497–509.
- Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF *et al.* (2001). Depression, heart rate variability, and acute myocardial infarction. *Circulation* 104: 2024–2028.
- Casey DP, Curry TB, Joyner MJ, Charkoudian N, Hart EC (2011). Relationship between muscle sympathetic nerve activity and aortic wave reflection characteristics in young men and women. *Hypertension* 57: 421–427.
- Casey DP, Curry TB, Joyner MJ, Charkoudian N, Hart EC (2012). Acute beta-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes. *Hypertension* 59: 145–150.
- Catananti C, Liperoti R, Settanni S, Lattanzio F, Bernabei R, Fialova D *et al.* (2009). Heart failure and adverse drug reactions among hospitalized older adults. *Clin Pharmacol Ther* 86: 307–310.

- Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL *et al.* (2008). Prevention of bone loss after withdrawal of tamoxifen. *Endocr Pract* 14: 162–167.
- Cross HR, Murphy E, Koch WJ, Steenbergen C (2002). Male and female mice overexpressing the beta(2)-adrenergic receptor exhibit differences in ischemia/reperfusion injury: role of nitric oxide. *Cardiovasc Res* 53: 662–671.
- Dadashzadeh S, Javadian B, Sadeghian S (2006). The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. *Biopharm Drug Dispos* 27: 329–334.
- Di Diego JM, Cordeiro JM, Goodrow RJ, Fish JM, Zygmunt AC, Perez GJ *et al.* (2002). Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. *Circulation* 106: 2004–2011.
- Dostalek M, Akhlaghi F, Puzanovova M (2012). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. *Clin Pharmacokinet* 51: 481–499.
- Drici MD, Clement N (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. *Drug Saf* 24: 575–585.
- Dubey RK, Oparil S, Imthurn B, Jackson EK (2002). Sex hormones and hypertension. *Cardiovasc Res* 53: 688–708.
- Duprez DA (2004). Is the female heart more sensitive to aldosterone for early remodeling? *Hypertension* 43: 936–937.
- Eidelman O, Jozwik C, Huang W, Srivastava M, Rothwell SW, Jacobowitz DM *et al.* (2010). Gender dependence for a subset of the low-abundance signaling proteome in human platelets. *Hum Genomics Proteomics* 2010: 164906.
- El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-Lacava A, Schwaab R *et al.* (2007). Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. *Hum Genet* 122: 505–514.
- El-Menyar A, Zubaid M, Rashed W, Almahmeed W, Al-Lawati J, Sulaiman K *et al.* (2009). Comparison of men and women with acute coronary syndrome in six Middle Eastern countries. *Am J Cardiol* 104: 1018–1022.
- Elovainio M, Ferrie JE, Singh-Manoux A, Shipley M, Batty GD, Head J *et al.* (2011). Socioeconomic differences in cardiometabolic factors: social causation or health-related selection? Evidence from the Whitehall II Cohort Study, 1991–2004. *Am J Epidemiol* 174: 779–789.
- Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M (2012). Organic anion transporters and their implications in pharmacotherapy. *Pharmacol Rev* 64: 421–449.
- Enomoto A, Endou H (2005). Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. *Clin Exp Nephrol* 9: 195–205.
- Enriquez JR, Pratap P, Zbilut JP, Calvin JE, Volgman AS (2008). Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, beta-blockers, or statins. *Gend Med* 5: 53–61.
- European Medicines Agency (2010). Guideline on the Investigation of Bioequivalence. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (accessed 3/1/2013).
- Fan X, Han Y, Sun K, Wang Y, Xin Y, Bai Y *et al.* (2008). Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension. *Ann Pharmacother* 42: 1772–1781.
- Faraday N, Goldschmidt-Clermont PJ, Bray PF (1997). Gender differences in platelet GPIIb-IIIa activation. *Thromb Haemost* 77: 748–754.
- FDA (2010). Evaluation of Gender Differences in Clinical Investigations – Information Sheet Guidance for Institutional Review Boards and Clinical Investigators: U. S. Department of Health and Human Services.
- Fischer M, Baessler A, Schunkert H (2002). Renin angiotensin system and gender differences in the cardiovascular system. *Cardiovasc Res* 53: 672–677.
- Fish JM, Antzelevitch C (2003). Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. *J Electrocardiol* 36 (Suppl.): 173–179.
- Franconi F, Brunelleschi S, Steardo L, Cuomo V (2007). Gender differences in drug responses. *Pharmacol Res* 55: 81–95.
- Franconi F, Seghieri G, Canu S, Straface E, Campesi I, Malorni W (2008). Are the available experimental models of type 2 diabetes appropriate for a gender perspective? *Pharmacol Res* 57: 6–18.
- Franconi F, Carru C, Malorni W, Vella S, Mercurio G (2011a). The effect of sex/gender on cardiovascular pharmacology. *Curr Pharm Des* 17: 1095–1107.
- Franconi F, Carru C, Spoleitini I, Malorni W, Vella S, Mercurio G *et al.* (2011b). A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. *Ther Deliv* 2: 1437–1453.
- Franconi F, Campesi I, Occhioni S, Antonini P, Murphy MF (2012). Sex and gender in adverse drug events, addiction, and placebo. *Handb Exp Pharmacol* 214: 107–126.
- Freire AC, Basit AW, Choudhary R, Piong CW, Merchant HA (2011). Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery. *Int J Pharm* 415: 15–28.
- Frieler RA, Ray JJ, Meng H, Ramnarayanan SP, Usher MG, Su EJ *et al.* (2012). Myeloid mineralocorticoid receptor during experimental ischemic stroke: effects of model and sex. *J Am Heart Assoc* 1: e002584.
- Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB *et al.* (2012). Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. *Chest* 141: 20–26.
- Gaborit N, Varro A, Le Bouter S, Szuts V, Escande D, Nattel S *et al.* (2010). Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. *J Mol Cell Cardiol* 49: 639–646.
- Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P (2010). Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. *Drug Metab Dispos* 38: 2204–2209.
- Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004). Sex differences in pharmacokinetics and pharmacodynamics. *Annu Rev Pharmacol Toxicol* 44: 499–523.
- Ghiadoni L, Donald AE, Cropley M, Mullen MJ, Oakley G, Taylor M *et al.* (2000). Mental stress induces transient endothelial dysfunction in humans. *Circulation* 102: 2473–2478.
- Gillies GE, McArthur S (2010). Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. *Pharmacol Rev* 62: 155–198.
- Glaser R, Sheridan J, Malarkey WB, MacCallum RC, Kiecolt-Glaser JK (2000). Chronic stress modulates the immune response to a pneumococcal pneumonia vaccine. *Psychosom Med* 62: 804–807.

- Greenspan JD, Craft RM, LeResche L, Arendt-Nielsen L, Berkley KJ, Fillingim RB *et al.* (2007). Studying sex and gender differences in pain and analgesia: a consensus report. *Pain* 132 (Suppl. 1): S26–S45.
- Groves CE, Suhre WB, Cherrington NJ, Wright SH (2006). Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. *J Pharmacol Exp Ther* 316: 743–752.
- Gupta SK, Atkinson L, Tu T, Longstreth JA (1995). Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. *Br J Clin Pharmacol* 40: 325–331.
- Haack S, Seeringer A, Thurmann PA, Becker T, Kirchheiner J (2009). Sex-specific differences in side effects of psychotropic drugs: genes or gender? *Pharmacogenomics* 10: 1511–1526.
- Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K *et al.* (2002). The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. *J Hypertens* 20: 2089–2093.
- Haltia LT, Rinne JO, Helin S, Parkkola R, Nagren K, Kaasinen V (2008). Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function. *Synapse* 62: 682–688.
- Halvorsen S, Eritsland J, Abdelnoor M, Holst Hansen C, Risoe C, Midtbo K *et al.* (2009). Gender differences in management and outcome of acute myocardial infarctions treated in 2006–2007. *Cardiology* 114: 83–88.
- Hanley MJ, Abernethy DR, Greenblatt DJ (2010). Effect of obesity on the pharmacokinetics of drugs in humans. *Clin Pharmacokinet* 49: 71–87.
- Hart EC, Joyner MJ (2010). The curse of the sympathetic nervous system: are men or women more unfortunate? *J Physiol* 588: 4345–4346.
- Health Canada (1997). Drugs and Health Products. Policy Issue from the Drugs Directorate: Inclusion of Women in Clinical Trials During Drug Development.
- Higgins LG, Hayes JD (2011). Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. *Drug Metab Rev* 43: 92–137.
- Huang HJ, Tsai ML, Chen YW, Chen SH (2011). Quantitative shot-gun proteomics and MS-based activity assay for revealing gender differences in enzyme contents for rat liver microsome. *J Proteomics* 74: 2734–2744.
- Institute of Medicine (2010). Women's Health Research: Progress, Pitfalls, and Promise. National Academies Press: Washington, DC.
- Jackevicius CA, Li P, Tu JV (2008). Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. *Circulation* 117: 1028–1036.
- James AF, Choisy SC, Hancox JC (2007). Recent advances in understanding sex differences in cardiac repolarization. *Prog Biophys Mol Biol* 94: 265–319.
- Janse de Jonge XA, Boot CR, Thom JM, Ruell PA, Thompson MW (2001). The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans. *J Physiol* 530: 161–166.
- Jarugula V, Yeh CM, Howard D, Bush C, Keefe DL, Dole WP (2010). Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren. *J Clin Pharmacol* 50: 1358–1366.
- Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V (2005). Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. *Eur Heart J* 26: 1585–1595.
- Johnell K, Weitoft GR, Fastbom J (2009). Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. *Ann Pharmacother* 43: 1233–1238.
- Johnson M, Ramey E, Ramwell PW (1975). Sex and age differences in human platelet aggregation. *Nature* 253: 355–357.
- Jones SG, Momin SR, Good MW, Shea TK, Patric K (2009). Distal upper and lower limb fractures associated with thiazolidinedione use. *Am J Manag Care* 15: 491–496.
- Journath G, Hellenius ML, Carlsson AC, Wandell PE, Nilsson PM (2010). Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment. *Blood Press* 19: 240–248.
- Kaminsky Z, Wang SC, Petronis A (2006). Complex disease, gender and epigenetics. *Ann Med* 38: 530–544.
- Kanashiro-Takeuchi RM, Heidecker B, Lamirault G, Dharamsi JW, Hare JM (2009). Sex-specific impact of aldosterone receptor antagonism on ventricular remodeling and gene expression after myocardial infarction. *Clin Transl Sci* 2: 134–142.
- Kando JC, Yonkers KA, Cole JO (1995). Gender as a risk factor for adverse events to medications. *Drugs* 50: 1–6.
- Kirchmayer U, Agabiti N, Belleudi V, Davoli M, Fusco D, Stafoggia M *et al.* (2012). Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: a population-based cohort study in Rome, Italy. *J Clin Pharm Ther* 37: 37–44.
- Kittikulsuth W, Sullivan JC, Pollock DM (2013). ET-1 actions in the kidney: evidence for sex differences. *Br J Pharmacol* 168: 318–326.
- Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D *et al.* (2000). Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. *Hypertension Optimal Treatment*. *J Hypertens* 18: 629–642.
- Klassen GA, Yeung PF, Barclay KD, Hung OR, Pollak PT, Buckley SJ (1995). Gender differences in exercise and recovery blood pressure responses in normal volunteers given diltiazem. *J Clin Pharmacol* 35: 1144–1149.
- Kloner RA, Sowers JR, DiBona GF, Gaffney M, Wein M (1996). Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. *Am J Cardiol* 77: 713–722.
- Kneale BJ, Chowienzyk PJ, Brett SE, Coltart DJ, Ritter JM (2000). Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. *J Am Coll Cardiol* 36: 1233–1238.
- Kong B, Csanaky IL, Aleksunes LM, Patni M, Chen Q, Ma X *et al.* (2012). Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity. *Toxicol Appl Pharmacol* 261: 189–195.
- Kostis WJ (2012). Absolute risk reduction due to statin use according to sex. *J Am Coll Cardiol* 60: 1580.
- Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB (2012). Meta-analysis of statin effects in women versus men. *J Am Coll Cardiol* 59: 572–582.
- Krantz DS, Schaeffer MA, Davia JE, Dembroski TM, MacDougall JM, Shaffer RT (1981). Extent of coronary atherosclerosis, type A behavior, and cardiovascular response to social interaction. *Psychophysiology* 18: 654–664.

- Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB (2000). Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. *Clin Pharmacol Ther* 68: 286–292.
- van Kuilenburg AB, Meinsma R, van Gennip AH (2004). Pyrimidine degradation defects and severe 5-fluorouracil toxicity. *Nucleosides Nucleotides Nucleic Acids* 23: 1371–1375.
- Kumar R, Nejatizadeh A, Arif E, Akhtar S, Gupta M, Tyagi S *et al.* (2009). Multi-locus interactions of vascular homeostasis genes in essential hypertension: a gender-based study. *Clin Chim Acta* 405: 87–93.
- Kumbhani DJ, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, Peacock WF *et al.* (2013). Predictors of adherence to performance measures in patients with acute myocardial infarction. *Am J Med* 126: 74. e71–79.
- Kurokawa J, Furukawa T (2013). Non-genomic action of sex steroid hormones and cardiac repolarization. *Biol Pharm Bull* 36: 8–12.
- Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF (2003). Platelet hyperreactivity in women from families with premature atherosclerosis. *J Am Med Womens Assoc* 58: 272–277.
- Lee HY, Cooke CE, Robertson TA (2008). Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. *J Manag Care Pharm* 14: 271–280.
- Legato MJ (2009). *Principles of Gender-Specific Medicine*, 2nd edn. Elsevier Academic Press: Amsterdam and Boston, MA.
- Leinwand LA (2003). Sex is a potent modifier of the cardiovascular system. *J Clin Invest* 112: 302–307.
- Li N, Hartley DP, Cherrington NJ, Klaassen CD (2002). Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. *J Pharmacol Exp Ther* 301: 551–560.
- Lieber A, Millasseau S, Bourhis L, Blacher J, Protogerou A, Levy BI *et al.* (2010). Aortic wave reflection in women and men. *Am J Physiol Heart Circ Physiol* 299: H236–H242.
- Lu H, Klaassen C (2008). Gender differences in mRNA expression of ATP-binding cassette efflux and bile acid transporters in kidney, liver, and intestine of 5/6 nephrectomized rats. *Drug Metab Dispos* 36: 16–23.
- Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ (1999). Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. *Clin Pharmacol Ther* 66: 594–601.
- Ma Y, Culver A, Rossouw J, Olendzki B, Merriam P, Lian B *et al.* (2012). Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? *Ther Adv Cardiovasc Dis* 7: 41–44.
- Mackay FJ, Pearce GL, Mann RD (1999). Cough and angiotensin II receptor antagonists: cause or confounding? *Br J Clin Pharmacol* 47: 111–114.
- Mahmoodzadeh S, Fliegner D, Dworatzek E (2012). Sex differences in animal models for cardiovascular diseases and the role of estrogen. *Handb Exp Pharmacol* 214: 23–48.
- Maiti S, Chen G (2003). Tamoxifen induction of aryl sulfotransferase and hydroxysteroid sulfotransferase in male and female rat liver and intestine. *Drug Metab Dispos* 31: 637–644.
- Marazziti D, Baroni S, Picchetti M, Piccinni A, Carlini M, Vatteroni E *et al.* (2013). Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex. *CNS Spectr* 18: 1–10.
- Marino M, Masella R, Bulzomi P, Campesi I, Malorni W, Franconi F (2011). Nutrition and human health from a sex-gender perspective. *Mol Aspects Med* 32: 1–70.
- Mas S, Gasso P, Alvarez S, Ortiz J, Sotoca JM, Francino A *et al.* (2011). Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. *Pharmacogenet Genomics* 21: 531–538.
- Maselli A, Matarrese P, Straface E, Canu S, Franconi F, Malorni W (2009). Cell sex: a new look at cell fate studies. *FASEB J* 23: 978–984.
- Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V *et al.* (2009). Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. *Circulation* 120: 1598–1605.
- Melloni C, Berger JS, Wang TY, Gunes F, Stebbins A, Pieper KS *et al.* (2010). Representation of women in randomized clinical trials of cardiovascular disease prevention. *Circ Cardiovasc Qual Outcomes* 3: 135–142.
- Mendelsohn ME, Karas RH (2005). Molecular and cellular basis of cardiovascular gender differences. *Science* 308: 1583–1587.
- Michaelis M, Hofmann PJ, Gotz F, Bartel C, Kienitz T, Quinkler M (2012). Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats. *Horm Metab Res* 44: 291–295.
- Miller VM, Jayachandran M, Hashimoto K, Heit JA, Owen WG (2008). Estrogen, inflammation, and platelet phenotype. *Gend Med* 5 (Suppl. A): S91–S102.
- Miller VM, Kaplan JR, Schork NJ, Ouyang P, Berga SL, Wenger NK *et al.* (2011). Strategies and methods to study sex differences in cardiovascular structure and function: a guide for basic scientists. *Biol Sex Differ* 2: 14.
- Mills PJ, Ziegler MG, Nelesen RA, Kennedy BP (1996). The effects of the menstrual cycle, race, and gender on adrenergic receptors and agonists. *Clin Pharmacol Ther* 60: 99–104.
- Mitoff PR, Gam D, Ivanov J, Al-hesayen A, Azevedo ER, Newton GE *et al.* (2011). Cardiac-specific sympathetic activation in men and women with and without heart failure. *Heart* 97: 382–387.
- Momen A, Gao Z, Cohen A, Khan T, Leuenberger UA, Sinoway LI (2010). Coronary vasoconstrictor responses are attenuated in young women as compared with age-matched men. *J Physiol* 588: 4007–4016.
- Morris ME, Lee HJ, Predko LM (2003). Gender differences in the membrane transport of endogenous and exogenous compounds. *Pharmacol Rev* 55: 229–240.
- Mosca L (2012). Controversy and consensus about statin use: it is not about the sex. *J Am Coll Cardiol* 59: 583–584.
- Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM *et al.* (2011). Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the American heart association. *Circulation* 123: 1243–1262.
- Mugford CA, Kedderis GL (1998). Sex-dependent metabolism of xenobiotics. *Drug Metab Rev* 30: 441–498.
- Muller JE, Abela GS, Nesto RW, Tofler GH (1994). Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. *J Am Coll Cardiol* 23: 809–813.
- Myburgh R, Hochfeld WE, Dodgen TM, Ker J, Pepper MS (2012). Cardiovascular pharmacogenetics. *Pharmacol Ther* 133: 280–290.

- Nakagawa M, Ooie T, Takahashi N, Taniguchi Y, Anan F, Yonemochi H *et al.* (2006). Influence of menstrual cycle on QT interval dynamics. *Pacing Clin Electrophysiol* 29: 607–613.
- Nattel S, Frelin Y, Gaborit N, Louault C, Demolombe S (2010). Ion-channel mRNA-expression profiling: insights into cardiac remodeling and arrhythmic substrates. *J Mol Cell Cardiol* 48: 96–105.
- Navarese EP, Buffon A, Andreotti F, Kozinski M, Welton N, Fabiszak T *et al.* (2013). Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. *Am J Cardiol* 111: 1123–1130.
- Navarro SL, Saracino MR, Makar KW, Thomas SS, Li L, Zheng Y *et al.* (2011). Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDP-glucuronosyltransferases. *J Nutrigenet Nutrigenomics* 4: 110–118.
- Nayak MK, Singh SK, Roy A, Prakash V, Kumar A, Dash D (2011). Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen. *Thromb Haemost* 106: 624–635.
- Ness GC, Chambers CM (2000). Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. *Proc Soc Exp Biol Med* 224: 8–19.
- Nicholas JS, Barron DH (1932). The use of sodium amytal in the production of anesthesia in the rat. *J Pharmacol Exp Ther* 46: 125–129.
- Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P *et al.* (2012). *European Cardiovascular Disease Statistics 2012*.
- Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. *Toxicol Appl Pharmacol* 199: 193–209.
- Patel H, Bell D, Molokhia M, Srishanmuganathan J, Patel M, Car J *et al.* (2007). Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005. *BMC Clin Pharmacol* 7: 9.
- Peterson ED, Shah BR, Parsons L, Pollack CV, Jr, French WJ, Canto JG *et al.* (2008). Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. *Am Heart J* 156: 1045–1055.
- Pinnow E, Sharma P, Parekh A, Gevorkian N, Uhl K (2009). Increasing participation of women in early phase clinical trials approved by the FDA. *Womens Health Issues* 19: 89–93.
- Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ *et al.* (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. *BMJ* 329: 15–19.
- Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A *et al.* (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 341: 709–717.
- Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B *et al.* (2003). Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 348: 1309–1321.
- Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S (1996). Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. *J Clin Oncol* 14: 78–84.
- Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ (2005). Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. *Arterioscler Thromb Vasc Biol* 25: 2435–2440.
- Quinn GP, Axelrod J, Brodie BB (1958). Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline. *Biochem Pharm* 1: 152–159.
- Raz L, Miller VM (2012). Considerations of sex and gender differences in preclinical and clinical trials. *Handb Exp Pharmacol* 214: 127–147.
- Regitz-Zagrosek V (2012). Sex and Gender Differences in Pharmacology., Vol. 214. Springer: London.
- Regitz-Zagrosek V, Seeland U (2012). Sex and gender differences in clinical medicine. *Handb Exp Pharmacol* 214: 3–22.
- Rigsby CS, Burch AE, Ogbi S, Pollock DM, Dorrance AM (2007). Intact female stroke-prone hypertensive rats lack responsiveness to mineralocorticoid receptor antagonists. *Am J Physiol Regul Integr Comp Physiol* 293: R1754–R1763.
- Rivero A, Curtis AB (2010). Sex differences in arrhythmias. *Curr Opin Cardiol* 25: 8–15.
- Rocha R, Stier CT, Jr (2001). Pathophysiological effects of aldosterone in cardiovascular tissues. *Trends Endocrinol Metab* 12: 308–314.
- Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E (2012). Discontinuation of statin therapy due to muscular side effects: a survey in real life. *Nutr Metab Cardiovasc Dis* 23: 871–875.
- Ross S, Buckalew LW (1985). Placebo agency: assessment of drug and placebo effects. In: White LTB, Schwartz GE (eds). *Placebo: Theory, Research and Mechanisms*. The Guilford Press: NewYork, pp. 67–82.
- Rost D, Kopplow K, Gehrke S, Mueller S, Friess H, Ittrich C *et al.* (2005). Gender-specific expression of liver organic anion transporters in rat. *Eur J Clin Invest* 35: 635–643.
- Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G (2008). Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. *Clin J Am Soc Nephrol* 3: 1511–1525.
- Saenz-Campos D, Bayes MC, Martin S, Barbanoj MJ, Jane F (1995). Gender related pharmacokinetics of diltiazem in healthy subjects. *Int J Clin Pharmacol Ther* 33: 397–400.
- Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ *et al.* (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 375: 735–742.
- Saxon L, Hiltunen AJ, Hjendahl P, Borg S (2001). Gender-related differences in response to placebo in benzodiazepine withdrawal: a single-blind pilot study. *Psychopharmacology (Berl)* 153: 231–237.
- Schmieder RE, Bohm M (2011). Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. *J Hum Hypertens* 25: 354–363.
- Schuetz EG, Furuya KN, Schuetz JD (1995). Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. *J Pharmacol Exp Ther* 275: 1011–1018.
- Schwartz GL, Turner ST, Chapman AB, Boerwinkle E (2002). Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. *Kidney Int* 62: 1718–1723.

- Schwartz JB (2007). The current state of knowledge on age, sex, and their interactions on clinical pharmacology. *Clin Pharmacol Ther* 82: 87–96.
- Seeland U, Regitz-Zagrosek V (2012). Sex and gender differences in cardiovascular drug therapy. *Handb Exp Pharmacol* 214: 211–236.
- Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL *et al.* (2000). Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. *Am J Med* 109: 489–492.
- Shammas FV, Dickstein K (1988). Clinical pharmacokinetics in heart failure. An updated review. *Clin Pharmacokinet* 15: 94–113.
- Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M *et al.* (2003). Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. *J Am Coll Cardiol* 41: 1529–1538.
- Sikdar KC, Alaghebandan R, MacDonald D, Barrett B, Collins KD, Donnan J *et al.* (2010). Adverse drug events in adult patients leading to emergency department visits. *Ann Pharmacother* 44: 641–649.
- Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH *et al.* (1988). Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. *JAMA* 260: 967–970.
- Soldin OP, Mattison DR (2009). Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet* 48: 143–157.
- Soldin OP, Chung SH, Mattison DR (2011). Sex differences in drug disposition. *J Biomed Biotechnol* 2011: 187103.
- Spoletini I, Vitale C, Malorni W, Rosano GM (2012). Sex differences in drug effects: interaction with sex hormones in adult life. *Handb Exp Pharmacol* 214: 91–105.
- Springer KW, Mager Stellman J, Jordan-Young RM (2011). Beyond a catalogue of differences: a theoretical frame and good practice guidelines for researching sex/gender in human health. *Soc Sci Med* 74: 1817–1824.
- Stramba-Badiale M (2009). Postmenopausal hormone therapy and the risk of cardiovascular disease. *J Cardiovasc Med (Hagerstown)* 10: 303–309.
- Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I *et al.* (2006). Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. *Eur Heart J* 27: 994–1005.
- Tuppin P, Neumann A, Danchin N, Weill A, Ricordeau P, de Peretti C *et al.* (2009). Combined secondary prevention after hospitalization for myocardial infarction in France: analysis from a large administrative database. *Arch Cardiovasc Dis* 102: 279–292.
- Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J *et al.* (2008). Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. *Eur Heart J* 29: 2669–2680.
- Turnbull F, Woodward M, Anna V (2010). Effectiveness of blood pressure lowering: evidence-based comparisons between men and women. *Expert Rev Cardiovasc Ther* 8: 199–209.
- Turnbull F, Arima H, Heeley E, Cass A, Chalmers J, Morgan C *et al.* (2011). Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. *Eur J Cardiovasc Prev Rehabil* 18: 498–503.
- Valera MC, Gratacap MP, Gourdy P, Lenfant F, Cabou C, Toutain CE *et al.* (2012). Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor alpha. *Blood* 120: 1703–1712.
- Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J *et al.* (2004). Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. *Hypertension* 43: 957–962.
- Veronesi G, Ferrario MM, Chambless LE, Segal R, Mancia G, Corrao G *et al.* (2010). Gender differences in the association between education and the incidence of cardiovascular events in Northern Italy. *Eur J Public Health* 21: 762–767.
- Wang TY, Angiolillo DJ, Cushman M, Sabatine MS, Bray PF, Smyth SS *et al.* (2012). Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. *J Am Coll Cardiol* 59: 891–900.
- Waxman DJ, Holloway MG (2009). Sex differences in the expression of hepatic drug metabolizing enzymes. *Mol Pharmacol* 76: 215–228.
- Weiner CP, Buhimschi C, Swaan P (2005). Drug-prescribing challenges during pregnancy. *Curr Obstet Gynecol* 15: 157–165.
- Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC *et al.* (1996). A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *N Engl J Med* 334: 1090–1094.
- Wheeldon NM, Newnham DM, Coutie WJ, Peters JA, McDevitt DG, Lipworth BJ (1994). Influence of sex-steroid hormones on the regulation of lymphocyte beta 2-adrenoceptors during the menstrual cycle. *Br J Clin Pharmacol* 37: 583–588.
- Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL *et al.* (2003). A comparison of outcomes with angiotensin-converting – enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 348: 583–592.
- Wolbrette D (2002). Gender differences in the proarrhythmic potential of QT-prolonging drugs. *Curr Womens Health Rep* 2: 105–109.
- Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ (2010). Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. *Pharmacogenet Genomics* 20: 532–536.
- Wu W, Kocarek TA, Runge-Morris M (2001). Sex-dependent regulation by dexamethasone of murine hydroxysteroid sulfotransferase gene expression. *Toxicol Lett* 119: 235–246.
- Yamashita K, Mikami Y, Ikeda M, Yamamura M, Kubozoe T, Urakami A *et al.* (2002). Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers. *Cancer Lett* 188: 231–236.
- Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF (2005). Aggregometry detects platelet hyperreactivity in healthy individuals. *Blood* 106: 2723–2729.
- Yeung PK, Prescott C, Haddad C, Montague TJ, McGregor C, Quilliam MA *et al.* (1993). Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose. *Eur J Drug Metab Pharmacokinet* 18: 199–206.
- Zanger UM, Schwab M (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* 138: 103–141.
- Zender R, Olshansky E (2009). Women's mental health: depression and anxiety. *Nurs Clin North Am* 44: 355–364.

Zhang FF, Cardarelli R, Carroll J, Fulda KG, Kaur M, Gonzalez K *et al.* (2011a). Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood. *Epigenetics* 6: 623–629.

Zhang Y, Klein K, Sugathan A, Nassery N, Dombkowski A, Zanger UM *et al.* (2011b). Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. *PLoS ONE* 6: e23506.

Zhou T, Chen Y, Huang C, Chen G (2012). Caffeine induction of sulfotransferases in rat liver and intestine. *J Appl Toxicol* 32: 804–809.

Zhu HJ, Appel DI, Jiang Y, Markowitz JS (2009). Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. *Drug Metab Dispos* 37: 1819–1825.

Zimmer KR, Lencina CL, Zimmer AR, Thiesen FV (2012). Influence of physical exercise and gender on acetylcholinesterase and butyrylcholinesterase activity in human blood samples. *Int J Environ Health Res* 22: 279–286.

Zotz RB, Klein M, Dauben HP, Moser C, Gams E, Scharf RE (2000). Prospective analysis after coronary-artery bypass grafting: platelet GP IIIa polymorphism (HPA-1b/PIA2) is a risk factor for bypass occlusion, myocardial infarction, and death. *Thromb Haemost* 83: 404–407.